TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: A Study Evaluating 24-Week and 48-Week Telaprevir-Based Regimen in Treatment Naïve Subjects With Genotype 1 Chronic Hepatitis C Who Achieve an Extended Rapid Viral Response

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Has not received any previous treatment with any approved or investigational drug or drug regimen for the treatment of hepatitis C~* Male and female subjects, 18 to 70 years of age, inclusive~* Genotype 1, chronic hepatitis C with detectable HCV RNA.~* Screening laboratory values, tests, and physical exam within acceptable ranges~* Able and willing to follow contraception requirements~* Able to read and understand, and willing to sign the informed consent form and abide by the study restrictions.~Exclusion Criteria:~* Subject has any contraindications to Pegasys® or Copegus® therapy~* Evidence of hepatic decompensation in cirrhotic subjects~* History of organ transplant~* History of, or any current medical condition which could impact the safety of the subject in participation in the study

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- T12PR24 (eRVR+) (Type: EXPERIMENTAL): Randomized Group: Telaprevir + Peg-IFN-alfa-2a + RBV for 12 weeks, followed by Peg-IFN-alfa-2a + RBV for 12 weeks; subjects achieved an extended rapid viral response (eRVR+) and were randomized to this group
- T12PR48 (eRVR+) (Type: EXPERIMENTAL): Randomized Group: Telaprevir + Peg-IFN-alfa-2a + RBV for 12 weeks, followed by Peg-IFN-alfa-2a + RBV for 36 weeks; subjects achieved an extended rapid viral response (eRVR+) and were randomized to this group
- T12PR48 (eRVR-) (Type: EXPERIMENTAL): Assigned Group: Telaprevir + Peg-IFN-alfa-2a + RBV for 12 weeks, followed by Peg-IFN-alfa-2a + RBV for 36 weeks; subjects did not achieve an extended rapid viral response and were assigned to this group
- Other (Type: EXPERIMENTAL): Other Group: Subjects who received at least 1 dose of study drug, but prematurely discontinued treatment before Week 20, were not randomized or assigned to a treatment regimen.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study In Patients With Type 2 Diabetes Mellitus

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: None
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
Inclusion criteria:~* A clinical diagnosis type 2 diabetes mellitus.~* Women must not be pregnant or breastfeeding during the study and 30 days after the study.~* Must sign an informed consent form at the study clinic.~Exclusion criteria:~* Severe chronic diseases that would prevent from participating and completing the study by investigator's judgement.~* Use of an investigational drug within 30 days or 5 half lives before first dose of study medication.~* Insulin use for \> 1 week in past 3 months.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Global Study to Assess the Safety and Effectiveness of Edoxaban (DU-176b) vs Standard Practice of Dosing With Warfarin in Patients With Atrial Fibrillation

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* 21 years of age or older; male or female.~* Able to provide written informed consent.~* History of documented AF within the prior 12 months~* A moderate to high risk of stroke, as defined by CHADS2 index score of at least 2~Exclusion Criteria:~* Transient atrial fibrillation secondary to other reversible disorders~* Subjects with moderate or severe mitral stenosis, unresected atrial myxoma, or a mechanical heart valve~* Subjects with any contraindication for anticoagulant agents;~* Subjects with conditions associated with high risk of bleeding or have known or suspected hereditary or acquired bleeding disorders~* Females of childbearing potential including the following:~  * Females with a history of tubal-ligation~ * Females less than 2 years post-menopausal

- Gender: ALL
- Minimum Age: 21 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Warfarin/placebo edoxaban (Type: ACTIVE_COMPARATOR): Warfarin tablets plus placebo Edoxaban tablets
- high dose edoxaban/placebo warfarin (Type: EXPERIMENTAL): Edoxaban tablets (60mg) plus warfarin placebo tablets
- low dose edoxaban/placebo warfarin (Type: EXPERIMENTAL): Edoxaban tablets (30mg) plus warfarin placebo tablets

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Substance Use Treatment and Recovery Team (START)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Inpatient at CSMC~* Age 18 and older~* Screens positive for moderate to severe OAUDs based on the alcohol and opioid questions on the~* World Health Organization (WHO) Alcohol, Smoking, and Substance Involvement Screening Test (ASSIST).~* Speaks English as primary language~* The usual attending physician agrees to patient's participation~* Has decision-making capacity and is not gravely disabled~Exclusion Criteria:~* Currently receiving FDA-approved medication treatment for an opioid or alcohol use disorder~* Gravely disabled (per clinical judgement)~* Does not have decision-making capacity (per clinical judgement)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- START (Type: ACTIVE_COMPARATOR): START is a model of care based on Collaborative Care. START is team driven, population-focused, measurement based, and focused on promoting adoption of evidence-based interventions. The purpose of this model is to increase adoption of evidence-based interventions for opioid and alcohol use disorders, and to increase linkage to aftercare.~The components of the START intervention are as follows:~1. Triage~2. Engage, Assess, and Plan~3. Treat~4. Communicate and Coordinate~5. Follow up~6. Monitor
- Usual Care (Type: NO_INTERVENTION): Usual care for people with alcohol or opioid use disorder.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study to Evaluate 90-Day Safety of Tapentadol(CG5503) Immediate Release (IR) or Oxycodone Immediate Release in Patients With Chronic Pain

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* A clinical diagnosis of one of the following: low-back pain of non-malignant origin for at least 3 months, osteoarthritis of the knee or hip for at least 3 months~* require daily doses of analgesia medication for chronic pain that is consistent with or makes them candidates for treatment at Step 2 or higher of the WHO Pain Relief Ladder~* post-washout baseline pain intensity score \>4 on an 11-point numerical rating scale~Exclusion Criteria:~* History of seizure disorder or epilepsy~* uncontrolled hypertension~* currently treated with monoamine oxidase inhibitors~* systemic steroid therapy, excluding inhalers or topical steroids, within 3 months before screening~* history of malignancy within the past 2 years, with the exception of basal cell carcinoma

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Selective Complex Fractionated Atrial Electrograms (CFAE) Targeting for Atrial Fibrillation

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~Candidates for this study must meet ALL of the following criteria:~* Age ≥ 18 years old~* First-time ablation procedure for AF~* Symptomatic AF which has been refractory to at least one antiarrhythmic medication (AAD). Symptomatic patients are those who have been aware of their AF anytime within the last 5 years. Symptoms may include, but are not restricted to, palpitations, shortness of breath, chest pain, fatigue, or other symptoms, or any combination of the above~* One of the following must apply:~  * AF must either be PERSISTENT AF (non-US sites only) or HIGH BURDEN PAROXYSMAL AF - High burden paroxysmal AF is defined as episodes that terminate within 30 days and meet any ONE of the following criteria:~ * More than 1 episode of AF per month in the preceding 6 months with at least 1 episode lasting \>24 hours by symptoms,~ * LA size of \>/= 48 mm in the PLAX (parasternal long axis) view on echocardiography~ * LA volume \>/= 100 cc~ * Total AF history \>/= 10 years~* At least one episode of AF must have been documented by ECG, Holter, TTM, or telemetry strip within 24 months of inclusion in the study.~* Patients must be able and willing to provide written informed consent to participate in the study.~* Able and willing to comply with all pre-, post- and follow-up testing and requirements.~Exclusion Criteria:~Candidates will be excluded from the study if any of the following conditions apply:~* Patients with long-standing persistent AF \>1 year for which cardioversion (pharmacologic or electrical) has failed or will never be attempted.~* Patients with AF felt to be secondary to an obvious reversible cause.~* Patients with contraindications to systemic anticoagulation with heparin or Coumadin.~* Patients who have previously undergone atrial fibrillation ablation.~* Patients who are pregnant (by history of menses or pregnancy test if history is considered unreliable.~* Left atrial size ≥55 mm (PLAX view on echocardiography).

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- (1) targeted CFAE ablation (Type: ACTIVE_COMPARATOR): None
- (2) generalized CFAE ablation (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Clinical Evaluation of a Cochlear Implant Sound Processor

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
General Inclusion Criteria:~* Ability to provide Informed Consent~* 18 years of age or older~* Unilateral user of a HiResolutionTM Bionic Ear System (HiRes 90KTM, HiRes 90KTM Advantage, HiResTM Ultra, HiResTM Ultra 3D), including bilaterally implanted subjects that only use one implant in their everyday listening modality~* Minimum of 6 months of CI experience~* Having used a Naída CI Q70 or a Naída CI Q90 as their primary processor for a minimum of one month~* Presently using a current steering strategy~* At least moderate open-set speech recognition abilities with implant alone, as defined by achieving a score of ≥ 60% words correct in the AzBio in quiet test using the Naída CI Q90 research processor~* English language proficiency as determined by the investigator~* Willingness to use a BTE processor for the duration of the study~ARH Arm Inclusion Criteria~* Residual low frequency hearing sensitivity (pure tone average of \< 70 dB HL for 125, 250, and 500 Hz) and a severe-to-profound high-frequency sensorineural hearing loss (pure tone average of ≥ 70 dB HL for 1,000, 2,000, 3000, 4,000, and 8,000 Hz) in the implanted ear~* Willingness to use an in-canal acoustic earhook for the duration of the study~EO Arm Inclusion Criteria~• Severe-to-profound sensorineural hearing loss in the low (pure tone average of ≥ 70 dB HL for 125, 250, and 500 Hz) and high frequencies (pure tone average ≥ 70 dB HL for 1,000, 2,000, 3000, 4,000, and 8,000 Hz) in the implanted ear~Exclusion Criteria:~* Unrealistic expectations regarding potential benefits, risks and limitations of the investigational device as determined by the investigator~* Unwillingness or physical / cognitive inability of subject to comply with all investigational requirements as determined by the investigator

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Aidable Residual Hearing (ARH) Cohort (Type: OTHER): Control Device followed by experimental Device.
- Electric Only (EO) Cohort (Type: OTHER): Control Device followed by experimental Device.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study to Estimate the Effects of Hepatic Impairment on the Pharmacokinetics (PK) of PF-07321332

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Male and female participants who are classically healthy having no clinically relevant abnormalities. No known or suspected hepatic impairment~* Stable hepatic impairment that meets the criteria for Class B of the Child-Pugh Classification~Exclusion Criteria:~* Any condition possibly affecting drug absorption (eg, prior bariatric surgery, gastrectomy, ileal resection).~* Participants who have been vaccinated with COVID-19 vaccines within the past week of dosing~* A positive urine drug test, for illicit drugs, at Screening~* History of sensitivity reactions to ritonavir or any of the formulation components of PF-07321332 or ritonavir.~* eGFR \<60 mL/min/1.73m2 based on the Chronic Kidney Disease-Epidemiology Collaboration (CKD-EPI) equation~* Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) level ≥ upper limit of normal (ULN) (for healthy participants); AST or ALT \> 5x ULN (for hepatic impairment participants)~* Albumin \> ULN (for healthy participants);~* Prothrombin time \> ULN (for healthy participants);~* Total bilirubin level ≥1.5 × ULN \[NOTE: Participants with a history of Gilbert syndrome (and hence elevated total bilirubin) are eligible provided direct bilirubin level is ≤ ULN).

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: t

Study Arms:
- Cohort 1 (Type: EXPERIMENTAL): Healthy Volunteer
- Cohort 2 (Type: EXPERIMENTAL): Hepatic Impairment

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Cytoprotective Agent and Peptic Ulcer in Dual Antiplatelet :RCT

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2/PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Age 18-70 year-old~2. Had cardiovascular disease which needed clopidogrel and aspirin~3. Stable enough for gastroscopy~Exclusion Criteria:~1. Gastroscopy revealed peptic ulcer~2. Had contraindication for gastroscopy~3. Not allowed for gastroscopy by cardiologist

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- Repamipide (Type: ACTIVE_COMPARATOR): Rebamipide (100) 1 tab oral tid for 1 year or peptic ulcer occurred
- placebo (Type: PLACEBO_COMPARATOR): A placebo is a simulated or otherwise medically ineffectual treatment for a disease or other medical condition intended to deceive the recipient. It will be prescribed as the same regimen of Rabamipide.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Radiation Therapy With or Without Optional Tamoxifen in Treating Women With Ductal Carcinoma in Situ

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Ductal carcinoma in situ (DCIS) of the breast detected by mammogram at the time of diagnosis~  * Unicentric~ * Lesions ≤ 2.5 cm~ * Low nuclei grade (NG1) or intermediate nuclei grade (NG2) with necrosis in \< one third of the involved ducts~ * Inked margins ≥ 3 mm~ * Clinically node negative~ * Non-palpable~* No suspicious areas on post-operative mammogram taken within 12 weeks after final surgery~* No bloody nipple discharge~* No more than 12 weeks since prior final surgery (arm II only)~* Hormone receptor status:~  * Not specified~PATIENT CHARACTERISTICS:~Age:~* 26 and over~Sex:~* Female~Menopausal status:~* Not specified~Performance status:~* Not specified~Life expectancy:~* Not specified~Hematopoietic:~* Not specified~Hepatic:~* Not specified~Renal:~* Not specified~Other:~* Not pregnant or nursing~* No active connective tissue disorders (e.g., lupus or scleroderma)~* No prior malignancy within the past 5 years except adequately treated basal cell or squamous cell skin cancer or carcinoma in situ of the cervix~PRIOR CONCURRENT THERAPY:~Biologic therapy:~* Not specified~Chemotherapy:~* No prior chemotherapy~Endocrine therapy:~* No other concurrent hormonal therapy (e.g., raloxifene, hormone replacement therapy, or birth control pills)~Radiotherapy:~* No prior radiotherapy~Surgery:~* See Disease Characteristics

- Gender: FEMALE
- Minimum Age: 26 Years
- Maximum Age: 120 Years
- Healthy Volunteers: f

Study Arms:
- Observation +/- tamoxifen for 5 years (Type: ACTIVE_COMPARATOR): Observation +/- tamoxifen 20 mg per day for 5 years
- Radiation therapy +/- tamoxifen for 5 years (Type: EXPERIMENTAL): Radiation therapy to the whole breast +/- tamoxifen 20 mg per day for 5 years

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Baclofen for the Treatment of Alcohol Dependence

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2/PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of alcohol dependence according to ICD-10 (International Classification of Mental and Behavioural Disorders, 10th revision) and DSM-IV (Diagnostic and Statistical Manual of Mental Disorders, 4th revision) criteria~* An alcohol intake of at least two heavy drinking days per week on average (men ≥ 5 drinks per day; women ≥ 4 drinks per day) and an average overall consumption of 21 drinks per week or more for men and 14 drinks per week or more for women during the 4 weeks before detoxification (one standard drink is equal to 12 g absolute alcohol)~* Last alcohol consumption within 7-21 days before randomisation~* Sufficient German language capabilities~Exclusion Criteria:~* Pregnancy and/or currently breastfeeding~* Clinical significant medical conditions or observed abnormalities~* Psychiatric illness undergoing treatment with psychoactive drugs~* Epilepsy or epileptiform convulsions~* Addiction to drugs other than nicotine

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 64 Years
- Healthy Volunteers: f

Study Arms:
- Baclofen (Type: EXPERIMENTAL): None
- Placebo (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Clinical Study to Compare Efficacy and Safety of Casirivimab and Imdevimab Combination, Remdesivir and Favipravir in Hospitalized COVID-19 Patients

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE4
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~1. age more than 12 years old.~2. weight not less than 40 kg.~3. Moderate, sever or critical COVID-19 disease as defined by WHO.~4. PCR- confirmed patients to be Positive before inclusion.~Exclusion Criteria:~1. history of hypersensitivity or infusion related reactions after administration of monoclonal antibodies.~2. prior use of standard antiviral therapy (remedsvir or favipravir).~3. Current use of controversial antiviral therapy (hydroxychloroquine, ivermectin, nitazoxanide, oseltemavir, acyclovir, ribavirine, lopinvir/rotinvir, sofosfbuvir, decltasevir, semipirvir, azithromycin).~4. patients expected to die within 48 hours.

- Gender: ALL
- Minimum Age: 12 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- casirivimab and imdevimab (Type: EXPERIMENTAL): casirivimab and imdevimab, vials 1.2 gm (1200 mg of combined antibodies) diluted in 250 ml 0.9% sodium chloride solution as single I.V infusion over 30-60 minutes.
- Remdesivir (Type: EXPERIMENTAL): Remdesivir, vials Day1 (loading dose): 200 mg (two 100mg vials) diluted in 500ml 0.9% sodium chloride solution infused I.V over 60 minutes Day 2-5 or Day 2-10 (maintenance dose): 100 mg (one 100mg vial) in 250 ml 0.9% sodium chloride solution infused I.V over 30 minutes
- Favipravir (Type: EXPERIMENTAL): Favipravir, tablets Day 1 (loading dose): 1600 mg (8 tablets) or 1800 mg (9 tablets) orally or in Ryle tube / 12 hours Day 2-5 or day 2-10 (maintenance dose): 600 mg (3 tablets) or 800 mg (4 tablets) orally or in Ryle tube / 12 hours

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete